Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022
Retrieved on:
Friday, September 30, 2022
Apoptosis, Paclitaxel, Aileron, Fibroblast, Safety, Incidence, EMBO Molecular Medicine, FDA, Cyclophosphamide, Doxorubicin, ESDR, TAC, Form 10-K, Keratinocyte, Hair, Permanent Damage, Docetaxel, SID, U.S. Securities and Exchange Commission, Patient, Cancer, Breast cancer, Neutropenia, B cell, Toxic leukoencephalopathy, Coronavirus, Paus family, Private Securities Litigation Reform Act, Scalp, DNA repair, Security (finance), DNA, Taxane, Skin, Dystrophy, Annual report, Hair loss, Hair follicle, Pharmaceutical industry, Health insurance, Vaccine
It is yet another burden layered on top of their already-daunting fight against cancer, said Dr. Paus.
Key Points:
- It is yet another burden layered on top of their already-daunting fight against cancer, said Dr. Paus.
- Ailerons vision is to bring chemoprotection to all patients with p53-mutated cancer regardless of the type of cancer or chemotherapy.
- We look forward to our anticipated data readouts from that trial later this year and into 2023.
- Aileron previously conducted in vitro studies showing that ALRN-6924 protected human fibroblasts in cell culture from multiple chemotherapies, but not p53-mutant breast cancer cells.